Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jul;40(7):1584–1588. doi: 10.1128/aac.40.7.1584

Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice.

L J Smeijsters 1, H Nieuwenhuijs 1, R C Hermsen 1, G M Dorrestein 1, F F Franssen 1, J P Overdulve 1
PMCID: PMC163377  PMID: 8807044

Abstract

Plasmodium berghei-infected mice died with low levels of parasitemia after repeated intraperitoneal administration (five times at 15 mg kg of body weight-1 every other day) of the in vitro active antimalarial acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]. Toxicological studies showed that the main cause of death resulted from (S)-HPMPA-induced nephrotoxicity. Although concomitant intraperitoneal administration of the tubular epithelium transport blocker probenecid prevented (S)-HPMPA-induced toxicity, mice eventually died with a high level of parasitemia, despite repeated administration of high doses of (S)-HPMPA. The short half-life of (S)-HPMPA in plasma combined with the insusceptibility of the nonreplicative stages of the parasite to (S)-HPMPA could explain this failure to eradicate all parasites. Indeed, a low but sustained (calculated) level of 200 nM (S)-HPMPA in plasma completely cured P. berghei-infected mice. However, these mice, which received a total dose of only 28 mg kg-1 administered via osmotic pumps for 7 days, died because of the toxicity of the drug. These findings indicate that nephrotoxicity hinders the use of (S)-HPMPA as a drug against blood stage parasites. An alternative application of (S)-HPMPA as a potent prophylactic drug is discussed.

Full Text

The Full Text of this article is available as a PDF (252.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aduma P., Connelly M. C., Srinivas R. V., Fridland A. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol. 1995 Apr;47(4):816–822. [PubMed] [Google Scholar]
  2. Balzarini J., Hao Z., Herdewijn P., Johns D. G., De Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1499–1503. doi: 10.1073/pnas.88.4.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Balzarini J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm World Sci. 1994 Apr 15;16(2):113–126. doi: 10.1007/BF01880662. [DOI] [PubMed] [Google Scholar]
  4. Bischofberger N., Hitchcock M. J., Chen M. S., Barkhimer D. B., Cundy K. C., Kent K. M., Lacy S. A., Lee W. A., Li Z. H., Mendel D. B. 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother. 1994 Oct;38(10):2387–2391. doi: 10.1128/aac.38.10.2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cihlár T., Rosenberg I., Votruba I., Holý A. Transport of 9-(2-phosphonomethoxyethyl)adenine across plasma membrane of HeLa S3 cells is protein mediated. Antimicrob Agents Chemother. 1995 Jan;39(1):117–124. doi: 10.1128/aac.39.1.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cundy K. C., Petty B. G., Flaherty J., Fisher P. E., Polis M. A., Wachsman M., Lietman P. S., Lalezari J. P., Hitchcock M. J., Jaffe H. S. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995 Jun;39(6):1247–1252. doi: 10.1128/aac.39.6.1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Janse C. J., Boorsma E. G., Ramesar J., Grobbee M. J., Mons B. Host cell specificity and schizogony of Plasmodium berghei under different in vitro conditions. Int J Parasitol. 1989 Aug;19(5):509–514. doi: 10.1016/0020-7519(89)90080-5. [DOI] [PubMed] [Google Scholar]
  8. Lalezari J. P., Drew W. L., Glutzer E., James C., Miner D., Flaherty J., Fisher P. E., Cundy K., Hannigan J., Martin J. C. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis. 1995 Apr;171(4):788–796. doi: 10.1093/infdis/171.4.788. [DOI] [PubMed] [Google Scholar]
  9. Lalezari J. P., Drew W. L., Glutzer E., Miner D., Safrin S., Owen W. F., Jr, Davidson J. M., Fisher P. E., Jaffe H. S. Treatment with intravenous (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis. 1994 Sep;170(3):570–572. doi: 10.1093/infdis/170.3.570. [DOI] [PubMed] [Google Scholar]
  10. Naesens L., Balzarini J., De Clercq E. Pharmacokinetics in mice of the anti-retrovirus agent 9-(2-phosphonylmethoxyethyl)adenine. Drug Metab Dispos. 1992 Sep-Oct;20(5):747–752. [PubMed] [Google Scholar]
  11. Qian M. X., Finco T. S., Mehta M., Viswanathan C. T., Gallo J. M. Pharmacokinetic evaluation of drug interactions with zidovudine. I: Probenecid and zidovudine in monkeys. J Pharm Sci. 1991 Nov;80(11):1007–1011. doi: 10.1002/jps.2600801102. [DOI] [PubMed] [Google Scholar]
  12. Rensen P. C., van Dijk M. C., Havenaar E. C., Bijsterbosch M. K., Kruijt J. K., van Berkel T. J. Selective liver targeting of antivirals by recombinant chylomicrons--a new therapeutic approach to hepatitis B. Nat Med. 1995 Mar;1(3):221–225. doi: 10.1038/nm0395-221. [DOI] [PubMed] [Google Scholar]
  13. Smeijsters L. J., Zijlstra N. M., de Vries E., Franssen F. F., Janse C. J., Overdulve J. P. The effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine on nuclear and organellar DNA synthesis in erythrocytic schizogony in malaria. Mol Biochem Parasitol. 1994 Sep;67(1):115–124. doi: 10.1016/0166-6851(94)90101-5. [DOI] [PubMed] [Google Scholar]
  14. Srinivas R. V., Robbins B. L., Connelly M. C., Gong Y. F., Bischofberger N., Fridland A. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob Agents Chemother. 1993 Oct;37(10):2247–2250. doi: 10.1128/aac.37.10.2247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. de Vries E., Stam J. G., Franssen F. F., Nieuwenhuijs H., Chavalitshewinkoon P., de Clercq E., Overdulve J. P., van der Vliet P. C. Inhibition of the growth of Plasmodium falciparum and Plasmodium berghei by the DNA polymerase inhibitor HPMPA. Mol Biochem Parasitol. 1991 Jul;47(1):43–50. doi: 10.1016/0166-6851(91)90146-w. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES